EVerZom Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$1.03M
- Investors
-
18
EVerZom General Information
Description
Developer of regenerative biologics treatment designed for tissue healing and organ restoration. The company integrates cell modification, high-yield exosome generation, molecular loading, and formulation processes, enabling healthcare professionals to access patent-protected extracellular vesicle therapeutics with enhanced therapeutic potency, improved biodistribution, reduced immunogenicity, and potential for application across digestive disorders and organ damage indications.
Contact Information
Website
www.everzom.comCorporate Office
- 45 Rue des Saints-Pères
- 75006 Paris
- France
Corporate Office
- 45 Rue des Saints-Pères
- 75006 Paris
- France
EVerZom Timeline
EVerZom Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Equity Crowdfunding | 02-Jul-2025 | $1.03M | Completed | Generating Revenue | ||
| 10. Grant | 17-Jun-2025 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 8. Later Stage VC | 08-Jun-2025 | Completed | Generating Revenue | |||
| 7. Grant | 16-Jun-2021 | Completed | Generating Revenue | |||
| 6. Seed Round | 03-Dec-2020 | Completed | Generating Revenue | |||
| 5. Grant | 13-Dec-2019 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jul-2019 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 2. Accelerator/Incubator | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
EVerZom Patents
EVerZom Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4788352-A1 | Combination of extracellular vesicles and chemotherapeutic agent and uses thereof for the treatment of cancers such as peritoneal carcinomatosis | Pending | 02-Oct-2023 | ||
| WO-2025073799-A1 | Combination of extracellular vesicles and chemotherapeutic agent and uses thereof for the treatment of cancers such as peritoneal carcinomatosis | Inactive | 02-Oct-2023 |
EVerZom Signals
EVerZom Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| France 2030 | Government | |||
| Audacia | Growth/Expansion | Minority | ||
| Capital Cell | PE-Backed Company | Minority | ||
| Capital Grand Est | PE/Buyout | Minority | ||
| Sorbonne Venture | Venture Capital | Minority |
EVerZom FAQs
-
When was EVerZom founded?
EVerZom was founded in 2019.
-
Where is EVerZom headquartered?
EVerZom is headquartered in Paris, France.
-
What is the size of EVerZom?
EVerZom has 24 total employees.
-
What industry is EVerZom in?
EVerZom’s primary industry is Drug Discovery.
-
Is EVerZom a private or public company?
EVerZom is a Private company.
-
What is the current valuation of EVerZom?
The current valuation of EVerZom is .
-
What is EVerZom’s current revenue?
The current revenue for EVerZom is .
-
How much funding has EVerZom raised over time?
EVerZom has raised $15.1M.
-
Who are EVerZom’s investors?
France 2030, Audacia, Capital Cell, Capital Grand Est, and Sorbonne Venture are 5 of 18 investors who have invested in EVerZom.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process